Researchers discover new enzyme in cancer growth

Dec 03, 2008

While studying the mechanics of blood clots, researchers at the University of Oklahoma Health Sciences Center discovered a new enzyme that not only affects the blood, but seems to play a primary role in how cancer tumors expand and spread throughout the body. The research appeared in recent issues of the journal Blood and the Journal of Thrombosis and Haemostasis.

A research group at OU led by Patrick McKee first discovered the enzyme called sFAP in plasma. After studying the biochemical makeup of the protein and identifying the gene that controlled its function, they began to search gene sequencing databases worldwide to find what it was. They didn't find the enzyme listed for blood, but got a match with a virtually identical protein known to cause cell growth in tissue, including in cancer. With McKee's discovery that the protein also exists in blood, scientists have a new avenue to study the spread of cancer.

"One thing all cancer cells need as they grow is something that acts as scaffolding. They have to attach to the scaffolding to divide and migrate. This enzyme excavates space around a malignancy and helps create the scaffolding," said McKee, M.D., principle investigator on the project.

The main function of the original FAP protein that was known to exist in tissue is to accelerate tissue growth and expand cells during fetal development, the healing of severe wounds and during growth of selected cancers such as breast, lung, pancreatic and colon.

Other than in these situations, the original form of FAP is not normally expressed in tissues at all. When it does appear, the protein helps activated fibroblasts, which growing cancer cells are able to recruit and stimulate to multiply within the malignancy itself. This creates space and the framework on which cancer cells attach, divide and eventually spread.

If FAP could be inhibited, then cancer growth could be slowed or halted, which in combination with chemotherapy or radiation might offer the potential to actually cure the malignancy, the OU team believes.

McKee and his group of investigators hold one patent on the enzyme and three more are under review for the development of an inhibitor. Based on the discovery and numerous publications of their work, the OU Health Sciences Center recently received a $365,000 federal grant from the U.S. Department of Defense to work on an inhibitor with cancer investigators at the University of Arkansas for Medical Sciences.

Source: University of Oklahoma

Explore further: New guidelines for treating form of advanced breast cancer

add to favorites email to friend print save as pdf

Related Stories

A new synthetic amino acid for an emerging class of drugs

Aug 31, 2014

Swiss scientists have developed a new amino acid that can be used to modify the 3-D structure of therapeutic peptides. Insertion of the amino acid into bioactive peptides enhanced their binding affinity up to 40-fold. Peptides ...

New tool identifies therapeutic proteins in a 'snap'

Aug 21, 2014

(Phys.org) —In human and bacterial cells, glycosylation – the chemical process of attaching complex sugar molecules to proteins – is as fundamental as it gets, affecting every biological mechanism from cell signaling ...

Crystal structure of COP9 signalosome elucidated

Aug 13, 2014

Nicolas Thomä and his group at the Friedrich Miescher Institute for Biomedical Research have elucidated the crystal structure of the human COP9 signalosome, an important regulator of protein degradation. ...

Molecular gate that could keep cancer cells locked up

Jul 31, 2014

In a study published today in Genes & Development, Dr Christian Speck from the MRC Clinical Sciences Centre's DNA Replication group, in collaboration with Brookhaven National Laboratory (BNL), New York, ...

Recommended for you

User comments : 0